Clinical trials: Moderate-to-severe Psoriasis
Plaque Psoriasis
Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis
The purpose of the study is to assess the safety and efficacy of an injectable biologic and U0279 as combination therapy compared to that of an injectable biologic alone for severe plaque-type psoriasis.
- Trial name
- NCT00832364
- Testing
- Acitretin (also called U0279), Etanercept
- Where
- 3 sites in United States
- Sponsor
- Stiefel, a GSK Company
Psoriasis
A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to compare the efficacy of Guselkumab with commercially available active comparator Fumaderm initial/Fumaderm tablets for the treatment of adult participants with moderate to severe plaque-type…
- Trial name
- POLARIS (NCT02951533)
- Testing
- Guselkumab, Fumaric Acid Esters
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Janssen-Cilag G.m.b.H
Psoriasis
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety Secondary objectives of Part 1 are to evaluate…
- Trial name
- NCT03635099
- Testing
- BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted)
- Where
- 34 sites in United States, Canada and 1 more
- Volunteers
- 274 people
- Sponsor
- Boehringer Ingelheim
Plaque Type Psorisis
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
- Trial name
- SUPREME (NCT02394561)
- Testing
- Secukinumab
- Where
- 45 sites in Italy
- Volunteers
- 434 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque Psoriasis
This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).
This is an open-label, 2-arm parallel-group study in normal healthy subjects to evaluate pharmacokinetics, safety, tolerability of Bmab 1200 -autoinjector (AI) after single subcutaneous injection (45 mg) in comparison with Bmab…
- Trial name
- NCT06738277
- Testing
- Bmab 1200 (Biosimilar Ustekinumab)
- Where
- India
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Biocon Biologics UK Ltd
Plaque Psoriasis
Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis
The purpose of this study is to evaluate the psoriasis disease control over time in participants who had received Tildrakizumab for at least the last 5 years and have discontinued it and to describe blood and skin inflammatory…
- Trial name
- MODIFY (NCT04339595)
- Testing
- Tildrakizumab
- Where
- 3 sites in Poland
- Volunteers
- 47 people
- Sponsor
- Almirall, S.A.
Moderate to Severe Plaque Psoriasis
Open Label Continuation Study in Moderate to Severe Psoriasis
The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.
- Trial name
- NCT00626002
- Testing
- ABT-874
- Where
- 152 sites in United States, Austria and 12 more
- Volunteers
- 2,301 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
A Study of Ixekizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam)…
- Trial name
- NCT02993471
- Testing
- Drug Cocktail, Ixekizumab
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Brief Description of Focus of Study
A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06912165
- Testing
- WD-890 tablet
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Wenda Pharma Technology LTD.
Plaque Psoriasis
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
- Trial name
- CLARITY (NCT02826603)
- Testing
- Secukinumab, Ustekinumab
- Where
- 154 sites in United States, Canada and 9 more
- Volunteers
- 1,114 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease…
- Trial name
- NCT02295865
- Testing
- JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg
- Where
- 13 sites in United States, Poland
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Plaque Psoriasis
ChangE From Any Systemic psoriasiS therapY to Raptiva
To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.
- Trial name
- EASY (NCT00697593)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.
- Trial name
- OASIS-1 (NCT03482011)
- Testing
- Mirikizumab
- Where
- 69 sites in United States, Germany and 7 more
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the efficacy and safety of HB0017 in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05531682
- Testing
- HB0017
- Where
- 21 sites in China
- Volunteers
- 160 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriasis
Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.
This is a randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm®, in 200 adults with moderate to severe plaque type psoriasis who are…
- Trial name
- PRIME (NCT02474082)
- Testing
- Secukinumab, Fumaric acid
- Where
- 32 sites in Germany
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
APremilast After FumaRic Acid Ester Treatment
Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment
- Trial name
- APART (NCT02954081)
- Testing
- Phase I: Fumaric acid esters. Phase II: Apremilast
- Where
- Germany
- Volunteers
- 687 people
- Sponsor
- Amgen
Plaque Psoriasis
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it.
- Trial name
- NCT07250802
- Testing
- Zasocitinib
- Where
- 39 sites in United States, China and 5 more
- Volunteers
- 110 people
- Sponsor
- Takeda
Psoriasis
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
- Trial name
- NCT01008995
- Testing
- ustekinumab
- Where
- 9 sites in China
- Volunteers
- 322 people
- Sponsor
- Centocor, Inc.
Psoriasis
Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827
This Phase 1 study will evaluate safety, tolerability, PK and PD of AMG 827 when administered as a single SC or IV dose.
- Trial name
- NCT00867100
- Testing
- 700 mg IV, 350 mg SC, 140 mg SC
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Moderate-to-Severe Plaque Psoriasis
Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in Patients with Moderate-to-Severe Plaque Psoriasis
- Trial name
- NCT04839016
- Testing
- SHR-1314
- Volunteers
- 660 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.